An interventional study of SeQuent® Please NEO drug-coated balloon catheter and Current-generation drug-eluting stent in Coronary Artery Disease, Myocardial Ischemia and Acute Coronary Syndrome, sponsored by B. Braun Medical Industries Sdn. Bhd.. Active, not recruiting at 21 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-28.
Sponsored by B. Braun Medical Industries Sdn. Bhd. (part of B. Braun) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Coronary Artery Disease by B. Braun — 1 open to participants now, 3 under way, none of them phase 3. Coronary Artery Disease · B. Braun.
Among the 11 studies in Coronary Artery Disease by B. Braun, this one is the only one that started in 2023, is one of 4 with no phase, and was the 10th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →1 of the 11 studies in Coronary Artery Disease by B. Braun is open now, in 2 countries. Recruiting first, the newest first:
B. Braun Melsungen AG · Sites in Germany, Switzerland
Ages 18+
By country, each count listing its studies:
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2023.
This study's planned enrollment of 1,436 is above the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 260 across the 5 interventional studies, 2,090 across the 6 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under B. Braun Medical Industries Sdn. Bhd., one of the names counted as B. Braun. Under that name alone:
This is the only study on the registry with B. Braun Medical Industries Sdn. Bhd. as lead sponsor.
2 of the studies in Coronary Artery Disease by B. Braun that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05846893B. Braun Medical Industries Sdn. Bhd.Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease | 2027-05 |
| NCT07363161B. Braun Melsungen AGBASel Kosten-Effektivitäts-Trial: Drug-coated BALLoon (DCB) vs. Drug-eluting Stent (DES) Strategy in High-risk Patients With Coronary Artery Disease (CAD) | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies in Coronary Artery Disease by B. Braun, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Prospective, randomised, open-label, international multicenter trial to evaluate the safety and efficacy of drug-coated balloon (DCB) treatment compared to drug-eluting stenting (DES) in patients with large coronary artery disease.
Although several reports suggested that DCB application was safe for larger coronary artery lesions and showed good long-term outcomes, there is limited randomised controlled trial (RCT) data on the safety and efficacy of DCB in large coronary artery disease.
Therefore, the study aims to demonstrate the non-inferiority of the drug-coated balloon (DCB) treatment against current-generation drug-eluting stenting (DES) in patients with de novo lesions in large coronary artery disease (reference vessel diameter ≥3.0 mm by visual estimation).
The hypothesis of the study is the clinical outcomes of patients treated with DCB are non-inferior to those treated with current-generation DES.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient-related:
Lesion-related:
Exclusion Criteria:
Patient-related:
Lesion-related:
Patient will be excluded if meet any of the following angiographic exclusion criteria after lesion preparation:
(i) Flow limiting dissection with TIMI flow \< III (ii) Residual diameter stenosis >30%
* The case of persistent ischemic symptoms/signs is up to the operator's decision
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: SeQuent® Please NEO drug-coated balloon catheter
Device: Current-generation drug-eluting stent
Treatment of coronary artery disease with SeQuent® Please NEO for de novo lesions in native large coronary arteries
Treatment of coronary artery disease with current-generation drug-eluting stent for de novo lesions in native large coronary arteries
Net Adverse Clinical Event (NACE)
Net adverse clinical event (NACE): a composite of all-cause death, non-fatal myocardial infarction, clinically driven target vessel revascularization, or major bleeding (BARC type 3 to 5)
Time frame: At 1 year
All-cause death
Time frame: At 12, 24, and 36 months
Non-fatal myocardial infarction
Time frame: At 12, 24, and 36 months
Clinically driven target vessel revascularization
Time frame: At 12, 24, and 36 months
Major bleeding (BARC type 3 to 5)
Time frame: At 12, 24, and 36 months
Cardiac death
Time frame: At 12, 24, and 36 months
Target vessel myocardial infarction
Time frame: At 12, 24, and 36 months
Periprocedural myocardial infarction
Time frame: At 12, 24, and 36 months
Target lesion revascularization
Time frame: At 12, 24, and 36 months
Stent/lesion thrombosis in treated lesion defined according to the Academic Research Consortium-2 (ARC-2) criteria
Time frame: At 12, 24, and 36 months
Rehospitalization related to study endpoints
Rate of hospitalization related to study endpoints
Time frame: At 30 days, 12 months, 24 months, and 36 months
Stroke (ischemic and hemorrhagic)
Number of participants with stroke (ischemic and hemorrhagic)
Time frame: At 12, 24, and 36 months
Total angioplasty procedure time
Time frame: During the index procedure
Fluoroscopy time of the angioplasty procedure
Time frame: During the index procedure
Contrast volume of the angioplasty procedure
Time frame: During the index procedure
Number of devices (DCB/ DES) used for PCI treatment
Time frame: During the index procedure
Late lumen loss (LLL)
LLL is defined as: the minimal lumen diameter (MLD) immediately after PCI minus the MLD at the follow-up.
Time frame: At 9-12 months post-procedure
Percentage of diameter stenosis
Time frame: At 9-12 months post-procedure
Minimal lumen diameter
Time frame: At 9-12 months post-procedure
Binary restenosis
Time frame: At 9-12 months post-procedure
Quality of life analysis
Quality of life analysis using EQ-5D-5L questionnaire
Time frame: After 12, 24, and 36 months
Incidence of angina
Time frame: At baseline and 12 months
Dual Antiplatelet Therapy (DAPT) duration
Time frame: At 30 days, 6 months, and 12 months
Comparison of NACE between DCB vs. DES in sex difference, diabetes mellitus, and multivessel disease patients
Time frame: At 1 year
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2023 (actual). Primary completion is estimated for May 2027, 44 months after the start.
Of 177 industry-sponsored interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 40. This study's planned 44 months is above that.
Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.